Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,077 people get BCRX articles and Market Currents by email alert.

Get email alerts on BCRX »

BCRX

BioCryst Pharmaceuticals, Inc.

6/19/2013, 5:39 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 7, 6:08 AM BioCryst Pharm (BCRX): Q1 EPS of -$0.09 beats by $0.03. Revenue of $3.6M beats by $2.29M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, May 7, 12:05 AM Notable earnings before Tuesday’s open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC 2 Comments [Earnings]
Monday, May 6, 5:30 PM Notable earnings before Tuesday's open: ACM, AFAM, AKRX, ALLT, ARCC, ARIA, BCRX, CHTR, CMLP, CNK, CQB, CRZO, CVLT, DFT, DISCA, DTV, DWRE, EMR, ENDP, FE, FOSL, HCN, HFC, HPT, HSIC, KWK, LPX, NRG, NRGY, NVAX, OAK, OMX, PQ, PRGO, RIGL, SHOO, TA, TAP, TDG, TGH, TICC, TRGT, TW, WRES, XEC Comment! [Earnings]
Wednesday, April 24, 11:37 AM BioCryst Pharmaceuticals (BCRX +8.3%) pops again today on bird flu concerns out of China, this time that catalyst comes from comments made out of the World Health Organization today, saying that the H7N9 is "one of the most lethal" strains of the bird flu virus compared to one that has killed about 371 since 2003. Since being discovered in March, the H7N9 has killed 22 and inflected just over 100 people. Comment! [Healthcare, Global & FX, On the Move]
Tuesday, April 16, 10:44 AM Shares in BioCryst Pharmaceuticals (BCRX +3.8%) are higher today after the company announces it's completed its Type C meeting on peramivir with the FDA and confirmed that its proposed New Drug Application content supports a reviewable submission for the indication of acute uncomplicated influenza. The company says it's now in the process of requesting a pre-NDA meeting to reach agreement on a complete NDA submission and to address review issues identified in the minutes. Comment! [Healthcare, On the Move]
Tuesday, April 16, 9:10 AM Premarket gainers: NWBO +9%. GFI +7%. BCRX +7%. HK +7%. AU +7%. NG +6%. AUQ +6%. SAND +6%. GOLD +5%. KGC +5%.
Losers: LDK -16%. SRPT -11%. 1 Comment [On the Move]
Monday, April 15, 10:28 AM BioCryst (BCRX +5%) moves up again today, adding to last week's gains as the number of bird flu cases in China continues to increase. Recent reports now have the death toll at 14, with 61 confirmed cases. The stock has climbed nearly 21% in the past week, after China moved to expedite approval of it's anti-flu drug, Permavir, after six new cases of the H7N9 virus were diagnosed. Comment! [Healthcare, Global & FX, On the Move]
Monday, April 15, 9:15 AM Premarket gainers: S +16%. SVA +13%. BCRX +10%. LIFE +8%. NFP +7%. MGT +7%. TMO +6%. THRX +5%. NVAX +5%.
Losers: AAU -15%. MTL -10%. AUQ -11%. HMY -9%. NGD -8%. CEF -8%. SLW -8%. SAND -9%. KGC -7%. AUY -7%. GOLD -7%. MUX -7%. DSCO -7%. IAG -6%. SVM -6%. GG -6%. PAAS -6%. EGO -6%. AU -5%. CDE -5%. Comment! [On the Move]
Monday, April 15, 8:39 AM Biotechs rise in early trading as the death toll from the new avian flu strain jumps to 13. Sinovac (SVA) is preparing immunizations and can manufacture 30-40M doses annually, according to Bloomberg. Meanwhile, investors continue to bet BioCryst's (BCRX) peramavir could have a role to play. Premarket moves: SVA +9.6%, BCRX +7.4%, NVAX +5%. Comment! [On the Move, Healthcare]
Tuesday, April 9, 8:03 AM BioCryst Pharma (BCRX) gets an upgrade to Buy from Hold at MLV whose analyst Ed Arce called the stock "a complete turnaround story" yesterday. The stock has rallied hard on speculation the company's drug peramavir may play a role in helping China combat a new strain of avian flu. Some however, believe the hype is overdone. Shares +4.7% premarket. Comment!
Monday, April 8, 3:30 PM JMP Securities analyst Lisa Bayko says the rally in BioCryst Pharma (BCRX +10%) on the China/Permivir news is overdone. She points out that BCRX has no patent in China for Peramivir, hasn't been involved in any drug approval, and "won't receive economics from use there." BCRX appears to agree. saying it doesn't even have a partner or any in-country operations in the region. TheStreet.com's Adam Fuerstein quips that the drug developer "isn't likely to see a dime" from drug sales there. Comment! [Healthcare, On the Move]
Monday, April 8, 9:10 AM Premarket gainers: LUFK +38%. BSDM +34%. BCRX +18%. UNXL +15%. GOL +10%. TSL +7%.
Losers: OMPI -6%. DCTH -5%. Comment! [On the Move]
Monday, April 8, 8:28 AM BioCryst Pharmaceuticals (BCRX) looks to post outsized gains for the second straight session as China expedites approval for its Peramivir drug amid worries about a new strain of avian flu. The shares rose sharply on Friday as the death toll from the new virus rose to six. Shares +21% premarket. Comment! [Healthcare, On the Move]
Friday, April 5, 11:09 AM BioCryst Pharmaceuticals (BCRX +17.4%) pops on news that six deaths in China have been linked to a new strain of avian flu. BCRX is developing peramivir, which has been shown in preclinical studies to help treat highly virulent strains of influenza - including the bird flu strain known as the H5N1 virus. Other drug stocks moving higher on the news: Pure Bioscience (PURE +15.6%), Hemispherx BioPharma (HEB +13.3%), Sinovac Biotech (SVA +7.8%), and Novavax (NVAX +1.1%). Comment! [Healthcare, On the Move]
Monday, April 1, 9:11 AM Premarket gainers: KWK +33%. BCRX +30%. SNFCA +23%. TSLA +16%. AM +12%. VRNG +10%. PAL +6%. Comment! [On the Move]
Monday, April 1, 8:29 AM BioCryst Pharmaceuticals (BCRX) receives a letter from FDA which it says "outlines a pathway by which an NDA [could be filed] seeking regulatory approval of intravenous permavir." Last November, shares were nearly cut in half after permavir disappointed in clinical trials. Shares +15% premarket. Comment! [Healthcare]